Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up ...
An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Roche's sale of InterMune and Esbriet in the US comes as Boehringer revealed its own follow-up play in the IPF, category, ...
Hosted on MSN12d
Lung Health in the Post-Pandemic World: Why It Becomes Even More Critical As You AgeWith the World Health Organization estimating that over 20 million people died from the coronavirus pandemic, despite ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
After offering a deep dive last year into the recipe behind its lead lung fibrosis candidate, Insilico Medicine is now giving ...
New York, USA, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...
The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback